Actinium Pharmaceuticals, Inc. (ATNWW) financial statements (2020 and earlier)

Company profile

Business Address 275 MADISON AVENUE, 7TH FLOOR
NEW YORK, NY 10016
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
3/31/2018
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments14201014152127
Cash and cash equivalents14201014152127
Restricted cash and investments00   0 
Other undisclosed current assets0001001
Total current assets:15201014152228
Noncurrent Assets
Finance lease, right-of-use asset00 
Operating lease, right-of-use asset11 
Property, plant and equipment0000000
Restricted cash and investments      0
Other undisclosed noncurrent assets0020000
Total noncurrent assets:2221110
TOTAL ASSETS:16221215162328
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:5556456
Other undisclosed accounts payable and accrued liabilities5556456
Debt0000   
Derivative instruments and hedges, liabilities      0
Other undisclosed current liabilities  0    
Total current liabilities:6566456
Noncurrent Liabilities
Long-term debt and lease obligation, including:0000   
Capital lease obligations00   
Other undisclosed long-term debt and lease obligation000    
Other undisclosed noncurrent liabilities111    
Total noncurrent liabilities:1110   
Total liabilities:6676456
Stockholders' equity
Stockholders' equity attributable to parent101659121722
Common stock0000000
Additional paid in capital214213198196192192191
Accumulated deficit(204)(198)(193)(187)(181)(174)(169)
Total stockholders' equity:101659121722
TOTAL LIABILITIES AND EQUITY:16221215162328

Income statement (P&L) ($ in millions)

9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
3/31/2018
Q1
Operating expenses(7)(5)(6)(6)(6)(5)(6)
Operating loss:(7)(5)(6)(6)(6)(5)(6)
Nonoperating income0000000
Investment income, nonoperating    000
Net loss attributable to parent:(7)(5)(6)(6)(6)(5)(6)
Other undisclosed net loss available to common stockholders, basic (0)     
Net loss available to common stockholders, diluted:(7)(5)(6)(6)(6)(5)(6)

Comprehensive Income ($ in millions)

9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
3/31/2018
Q1
Net loss:(7)(5)(6)(6)(6)(5)(6)
Comprehensive loss, net of tax, attributable to parent:(7)(5)(6)(6)(6)(5)(6)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: